MorphoSys Settles Patent Lawsuit with Janssen and Genmab

MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced on 1/31/19 that in its lawsuit against Janssen Biotech and Genmab A/S, the parties have settled the dispute. As a result of this, the parties to the dispute have agreed to drop the mutual claims related to this litigation.

On April 4, 2016 MorphoSys had filed a lawsuit in the United States (U.S.) District Court of Delaware against Janssen Biotech, and Genmab, A/S for patent infringement of U.S. Patent Number 8,263,746. In 2017, a second and a third patent with US Patent Numbers 9,200,061 and 9,758,590 were added to the lawsuit. MorphoSys had sought redress for alleged infringement by Janssen's and Genmab's daratumumab, a CD38-directed monoclonal antibody for the treatment of multiple myeloma. MorphoSys is dismissing those claims and will not appeal from the previously-announced court order dated January 25, 2019. Janssen and Genmab are dismissing their counterclaims.